The influence of cost-effectiveness and other factors on NICE：（成本效益的影响和其他因素对好）.pdfVIP

The Influence of Cost-Effectiveness and Other Factors on NICE Decisions CHE Research Paper 93 The influence of cost-effectiveness and other factors on NICE decisions 1Helen Dakin 2Nancy Devlin 2 Yan Feng 3 Nigel Rice 2Phill O’Neill 4 David Parkin 1Health Economics Research Centre, University of Oxford, UK 2Office of Health Economics, London, UK 3Centre for Health Economics and Department of Economics and Related Studies, University of York, UK 4 Department of Primary Care and Public Health Sciences, King’s College London, UK November 2013 Background to series CHE Discussion Papers (DPs) began publication in 1983 as a means of making current research material more widely available to health economists and other potential users. So as to speed up the dissemination process, papers were originally published by CHE and distributed by post to a worldwide readership. The CHE Research Paper series takes over that function and provides access to current research output via web-based publication, although hard copy will continue to be available (but subject to charge). Acknowledgements We would like to thank Tony Culyer for his comments on the draft of this manuscript. We are grateful to HTAinSite© for allowing access to the data for this study. In particular, we wish to thank Pam Poppe, Iain Shield, Carmel Guarnieri and Zoe Philips, of Abacus International, for preparing the dataset for our analysis. Funding for this study was provided by a research grant provided by a consortium of British Pharmaceutical companies: Amgen, AstraZeneca, BMS, Celgene UK Ireland, GSK, Lilly UK, Merck, Merck Serono, Pfizer, Sanofi Aventis, Schering Plough, Takeda UK, and Wyeth. Views expressed in this paper are those of the authors and do not necessarily represent the views of the sponsors